Brian Pereira

Tufts Medical Center, Inc. owns and operates an academic medical center. It provides healthcare services and programs in the areas of allergy, anesthesiology, bariatric surgery, cancer, cardiology, colon and rectal, clinical nutrition, dentistry, dermatology, ENT/otolaryngology, endocrinology, diabetes and metabolism, gastroenterology, general surgery, geriatrics, hematology/oncology, hyperbaric medicine, infectious diseases, maternity, nephrology, neurology, neurosurgery, and nutrition. The firm also offers services in the areas of obstetrics and gynecology, occupational therapy, ophthalmology, orthopedics, otolaryngology, pain management, palliative care, pathology, pediatrics, physical medicine, physical therapy, plastic surgery, psychiatry, pulmonary, radiation oncology, radiology, rheumatology, speech language pathology and audiology, thoracic and transplant surgery, trauma surgery, urology, vascular surgery, wound healing, and weight and wellness. The company was founded in 1796 and is headquartered in Boston, MA.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. Its products include Makena and Feraheme. It focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It also manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Nephrocare Health Services Pvt Ltd. operates a chain of kidney care clinics. Its services include in-centre hemodialysis, home hemodialysis, dialysis on wheels, and holiday dialysis. The company was founded by Vikram Vuppala, Sandeep Gudibanda, and Kamal D. Shah on December 18, 2009 and is headquartered in Hyderabad, India.

Opsonix, Inc. manufactures and distributes medical devices. It commercializes and develops products to transform the treatment and diagnosis of sepsis. The company was founded on April 11, 2014 and is headquartered in Cambridge, MA.

ProKidney LLC develops therapies for kidney disease. The company was founded by Pablo Legorreta and is headquartered in Winston-Salem, NC.

Africa Healthcare Network Rwanda Ltd. operates kidney dialysis centers and hospitals. The company was founded by Nikhil Pereira-Kamath, Brian J.G. Pereira and Lloyd Vincent in 2015 and is headquartered in Kigali, South Africa.

Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a private company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million.